115 related articles for article (PubMed ID: 2787951)
21. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
22. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
23. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
[TBL] [Abstract][Full Text] [Related]
24. Adoptive immunotherapy in gastrointestine malignancies using interleukin-2. Current results and future prospects.
Marshall GD
Acta Chir Scand Suppl; 1989; 549():71-4. PubMed ID: 2784605
[No Abstract] [Full Text] [Related]
25. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Ettinghausen SE; Matory YL; Skibber JM; Shiloni E; Vetto JT
N Engl J Med; 1985 Dec; 313(23):1485-92. PubMed ID: 3903508
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy using lymphokine-activated killer cells.
Fowler JE
J Urol; 1988 Jan; 139(1):148-9. PubMed ID: 3257273
[No Abstract] [Full Text] [Related]
27. [Adoptive immunotherapy of malignant diseases with LAK cells].
Kimoto Y; Tanji Y; Tanaka T; Taguchi T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):687-92. PubMed ID: 3493732
[TBL] [Abstract][Full Text] [Related]
28. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.
Wang JC; Walle A; Novogrodsky A; Suthanthiran M; Silver RT; Bander NH; Rubin AL; Stenzel KH
J Clin Oncol; 1989 Dec; 7(12):1885-91. PubMed ID: 2555451
[TBL] [Abstract][Full Text] [Related]
29. Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
Marcus SL; Dutcher JP; Paietta E; Ciobanu N; Strauman J; Wiernik PH; Hutner SH; Frank O; Baker H
Cancer Res; 1987 Aug; 47(15):4208-12. PubMed ID: 3496958
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of therapeutic potential of interleukin 2-expanded tumor-infiltrating lymphocytes in squamous cell carcinoma of the head and neck.
Boscia R; Chen K; Johnson JT; Whiteside TL
Ann Otol Rhinol Laryngol; 1988; 97(4 Pt 1):414-21. PubMed ID: 3261562
[TBL] [Abstract][Full Text] [Related]
32. Lysis of primary hepatic tumours by lymphokine activated killer cells.
Hsieh KH; Shu SY; Lee CS; Chu CT; Yang CS; Chang KJ
Gut; 1987 Feb; 28(2):117-24. PubMed ID: 3030899
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
34. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
36. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
[TBL] [Abstract][Full Text] [Related]
37. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.
Favrot MC; Coze C; Combaret V; Gaspard M; Colin C; Franks C; Negrier S; Philip I; Philip T
Mol Biother; 1990 Mar; 2(1):32-7. PubMed ID: 2185792
[TBL] [Abstract][Full Text] [Related]
38. [Adoptive immunotherapy using cytapheresis].
Takago H; Sasakawa H; Kanizawa Y; Nojiri H; Ueno Y
Rinsho Ketsueki; 1986 Jul; 27(7):1242-6. PubMed ID: 3491233
[No Abstract] [Full Text] [Related]
39. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
[TBL] [Abstract][Full Text] [Related]
40. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]